Erectile Dysfunction – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Erectile Dysfunction – Pipeline Review, H2 2017’, provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction

The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects

The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Apricus Biosciences Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Biopharm GmbH

Can-Fite BioPharma Ltd

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Hanmi Pharmaceuticals Co Ltd

Humanetics Corp

IntelGenx Corp

Ion Channel Innovations LLC

iX Biopharma Ltd

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Monosol Rx LLC

N4 Pharma Plc

NAL Pharmaceuticals Ltd

Nanoform Cardiovascular Therapeutics Ltd

Palatin Technologies Inc

Pharmicell Co Ltd

SK Chemicals Co Ltd

Suda Ltd

XuanZhu Pharma Co Ltd

Yangtze River Pharmaceutical Group

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Erectile Dysfunction - Overview 8

Erectile Dysfunction - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Erectile Dysfunction - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Erectile Dysfunction - Companies Involved in Therapeutics Development 25

Apricus Biosciences Inc 25

Astellas Pharma Inc 25

Biolab Farmaceutica Ltda 26

Biopharm GmbH 26

Can-Fite BioPharma Ltd 27

Fabre-Kramer Pharmaceuticals Inc 27

Futura Medical Plc 28

Hanmi Pharmaceuticals Co Ltd 28

Humanetics Corp 29

IntelGenx Corp 29

Ion Channel Innovations LLC 30

iX Biopharma Ltd 30

Mezzion Pharma Co Ltd 31

Mitsubishi Tanabe Pharma Corp 31

Monosol Rx LLC 32

N4 Pharma Plc 32

NAL Pharmaceuticals Ltd 33

Nanoform Cardiovascular Therapeutics Ltd 33

Palatin Technologies Inc 34

Pharmicell Co Ltd 34

SK Chemicals Co Ltd 35

Suda Ltd 35

XuanZhu Pharma Co Ltd 36

Yangtze River Pharmaceutical Group 36

Yungjin Pharm Co Ltd 37

Erectile Dysfunction - Drug Profiles 38

alprostadil - Drug Profile 38

AP-185 - Drug Profile 45

avanafil - Drug Profile 46

BIO-300 - Drug Profile 48

BL-214 - Drug Profile 51

Cellgram-ED - Drug Profile 52

CF-602 - Drug Profile 53

fadanafil - Drug Profile 55

FKK-01PD - Drug Profile 56

HCP-1302 - Drug Profile 57

IPED-2015 - Drug Profile 58

MED-2002 - Drug Profile 59

MED-2005 - Drug Profile 62

mirabegron ER - Drug Profile 63

moxisylyte - Drug Profile 67

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile 68

pVAX-hSlo - Drug Profile 70

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 72

sildenafil - Drug Profile 74

sildenafil citrate - Drug Profile 75

sildenafil citrate - Drug Profile 76

sildenafil citrate - Drug Profile 77

sildenafil citrate - Drug Profile 78

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 79

SUD-003 - Drug Profile 80

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 82

T-6932 - Drug Profile 83

tadalafil - Drug Profile 84

tadalafil - Drug Profile 86

tadalafil - Drug Profile 87

tadalafil - Drug Profile 88

tadalafil - Drug Profile 89

TF-0092 - Drug Profile 90

TPN-729 - Drug Profile 91

TR-399 - Drug Profile 92

udenafil - Drug Profile 93

YBH-1603 - Drug Profile 97

Yonkenafil - Drug Profile 98

Erectile Dysfunction - Dormant Projects 99

Erectile Dysfunction - Discontinued Products 101

Erectile Dysfunction - Product Development Milestones 102

Featured News & Press Releases 102

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Tables

List of Tables

Number of Products under Development for Erectile Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Erectile Dysfunction – Pipeline by Apricus Biosciences Inc, H2 2017

Erectile Dysfunction – Pipeline by Astellas Pharma Inc, H2 2017

Erectile Dysfunction – Pipeline by Biolab Farmaceutica Ltda, H2 2017

Erectile Dysfunction – Pipeline by Biopharm GmbH, H2 2017

Erectile Dysfunction – Pipeline by Can-Fite BioPharma Ltd, H2 2017

Erectile Dysfunction – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017

Erectile Dysfunction – Pipeline by Futura Medical Plc, H2 2017

Erectile Dysfunction – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Erectile Dysfunction – Pipeline by Humanetics Corp, H2 2017

Erectile Dysfunction – Pipeline by IntelGenx Corp, H2 2017

Erectile Dysfunction – Pipeline by Ion Channel Innovations LLC, H2 2017

Erectile Dysfunction – Pipeline by iX Biopharma Ltd, H2 2017

Erectile Dysfunction – Pipeline by Mezzion Pharma Co Ltd, H2 2017

Erectile Dysfunction – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Erectile Dysfunction – Pipeline by Monosol Rx LLC, H2 2017

Erectile Dysfunction – Pipeline by N4 Pharma Plc, H2 2017

Erectile Dysfunction – Pipeline by NAL Pharmaceuticals Ltd, H2 2017

Erectile Dysfunction – Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017

Erectile Dysfunction – Pipeline by Palatin Technologies Inc, H2 2017

Erectile Dysfunction – Pipeline by Pharmicell Co Ltd, H2 2017

Erectile Dysfunction – Pipeline by SK Chemicals Co Ltd, H2 2017

Erectile Dysfunction – Pipeline by Suda Ltd, H2 2017

Erectile Dysfunction – Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Erectile Dysfunction – Pipeline by Yangtze River Pharmaceutical Group, H2 2017

Erectile Dysfunction – Pipeline by Yungjin Pharm Co Ltd, H2 2017

Erectile Dysfunction – Dormant Projects, H2 2017

Erectile Dysfunction – Dormant Projects, H2 2017 (Contd..1), H2 2017

Erectile Dysfunction – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Erectile Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports